Aditx Therapeutics (ADTX)
(Delayed Data from NSDQ)
$2.41 USD
+0.02 (0.84%)
Updated Apr 29, 2024 03:59 PM ET
After-Market: $2.40 -0.01 (-0.41%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Income Statements
Fiscal Year end for Aditxt Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 1 | 0 | 0 | 0 |
Cost Of Goods | 1 | 1 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 26 | 26 | 42 | 9 | 6 |
Income After Depreciation & Amortization | -26 | -25 | -42 | -9 | -6 |
Non-Operating Income | -2 | -1 | -4 | 0 | 0 |
Interest Expense | 4 | 1 | 0 | 0 | 0 |
Pretax Income | -32 | -28 | -46 | -9 | -6 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -32 | -28 | -46 | -9 | -6 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -32 | -28 | -46 | -9 | -6 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -23 | -23 | -40 | -9 | -6 |
Depreciation & Amortization (Cash Flow) | 3 | 2 | 2 | 0 | 0 |
Income After Depreciation & Amortization | -26 | -25 | -42 | -9 | -6 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.30 | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -108.15 | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | -108.15 | -595.60 | -4,860.00 | -2,660.00 | NA |
Fiscal Year end for Aditxt Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.08 | 0.12 | 0.22 | 0.22 |
Cost Of Goods | NA | 0.29 | 0.11 | 0.19 | 0.18 |
Gross Profit | NA | -0.20 | 0.02 | 0.04 | 0.04 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 7.74 | 8.11 | 4.26 | 5.82 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -7.94 | -8.09 | -4.22 | -5.78 |
Non-Operating Income | NA | -1.22 | -0.74 | -0.16 | 0.00 |
Interest Expense | NA | 1.81 | 0.91 | 1.29 | 0.20 |
Pretax Income | NA | -10.98 | -9.75 | -5.68 | -5.98 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | -0.01 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -10.98 | -9.75 | -5.68 | -5.98 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -10.97 | -9.75 | -5.68 | -5.98 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 0.20 | 0.15 | 0.11 |
Diluted EPS Before Non-Recurring Items | NA | NA | -48.77 | -36.80 | -52.40 |
Diluted Net EPS (GAAP) | NA | 29.82 | -48.77 | -36.80 | -52.40 |